🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

tucatinib +H (+fulvestrant for HR+) for HER2m mBC 87% HR+ ORR 41.9% DOR 18.2 mo mPFS 10.9 mo #ESMOBreast25 ESMO - Eur. Oncology

Could immunotherapy make a difference in stage I TNBC? #ESMOBreast25 ESMO - Eur. Oncology

ROSALINE, led by Philippe Aftimos, MD  & presented by Soraia Lobo-Martins 1st preop ET trial dedicated to lobular BC ET + entrectinib showed 0% RCB 0/1 in HR+/HER2– ILC. MRI-based ORR = 49% ➡️ Biomarker analyses underway Another example that ILC-focused trials are feasible! #ESMOBreast25

🔬 ¿Toda respuesta patológica completa garantiza buen pronóstico? No siempre. En #ESMOBreast25, la Dra. Elia Seguí, MD analiza el cáncer de mama triple negativo: 🧠 TILs y estado ganglionar podrían identificar pacientes con mayor riesgo, incluso tras respuesta completa. 💡 Un

5 sesiones llevamos ya del #SOLTIyoung Development Program 😊 ¿Cómo pasa tan rápido? En esta ocasión, ha tocado manejo de las metástasis cerebrales en enfermedad HER2+ de la mano de dos de las mejores expertas nacionales sobre el tema: la Dra. María Martínez (Hospital del Mar ) y

Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO25 Patient population considerations: 1) De novo patients (capped at 50%): these patients are more likely to respond durably and possibly even be cured in

Building off of Nancy Lin, MD and Dr Pablo Leone’s data with carboplatin/bevacizumab in brain metastases. 77% intracranial response rate of carbo, bev, and PD-1 inhibition in TNBC brain metastases shows excellent potential. Time to try this with bispecifics. #bcsm #ASCO25

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment. #ASCO25

Dana-Farber’s Breast Oncology Center is ready for a practice-changing Metastatic Breast Cancer Session at #ASCO25. Here we go!!!

Late-breaking research at #ASCO25 in triple-negative breast cancer: Dana-Farber's Sara Tolaney presents on phase 3 findings that show sacituzumab govitecan plus pembrolizumab could be a new first-line treatment option for PDL1+ patients with metastatic triple-negative

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. ASCO #ASCO25 OncoAlert

Dream team breast cancer researchers Dana-Farber’s Breast Oncology Center Dana-Farber pioneering advancement therapeutics for patients #bcsm ASCO Sara Tolaney Ann Partridge MD, MPH Harold J. Burstein, MD, PhD, FASCO Nancy Lin, MD Erica Mayer Dr Sarah Sammons Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Ada Waks Heather Parsons Ilana Schlam Elahe Salehi DNP Paolo Tarantino

Recent rationale in metastatic breast cancer for bringing ADCs into the 1st line has quoted very high 1st line attrition rates of patients not making it to second line. This study is likely more accurate of 2025 patients. In total, 9% of patients with MBC do not make it to